Cited 3 times in
Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김도영 | - |
dc.contributor.author | 김범경 | - |
dc.contributor.author | 김승업 | - |
dc.contributor.author | 박준용 | - |
dc.contributor.author | 범승훈 | - |
dc.contributor.author | 성진실 | - |
dc.contributor.author | 안상훈 | - |
dc.contributor.author | 원종윤 | - |
dc.contributor.author | 이재승 | - |
dc.contributor.author | 이혜원 | - |
dc.contributor.author | 최혜진 | - |
dc.contributor.author | 한광협 | - |
dc.date.accessioned | 2021-09-29T02:15:43Z | - |
dc.date.available | 2021-09-29T02:15:43Z | - |
dc.date.issued | 2021-10 | - |
dc.identifier.issn | 0171-5216 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/184798 | - |
dc.description.abstract | Background: We compared the clinical efficacies of hepatic arterial infusion chemotherapy (HAIC) vs. sorafenib as sequential maintenance therapy following liver-directed concurrent chemoradiotherapy (LD-CCRT) for locally advanced-stage hepatocellular carcinoma (HCC). Methods: Patients undergoing HAIC with 5-fluorouracil and cisplatin (HAIC-maintain group, n = 151) or sorafenib (Sorafenib-maintain group, n = 37) after LD-CCRT were consecutively enrolled. The study endpoints were overall survival (OS), progression-free survival (PFS), and treatment response rates. Results: The median OS among HAIC-maintain and Sorafenib-maintain groups were 15.9 and 24.3 months (p = 0.287), whereas the median PFS were 8.1 and 9.1 months (p = 0.651), respectively. During the planned treatments, the radiological objective response rate (54.3% vs. 64.9%; p = 0.246), and conversion rate to surgical resection or liver transplantation after successful down-staging (15.9% vs. 18.9%; p = 0.657) were comparable between the HAIC-maintain and Sorafenib-maintain groups. Similar results were found after the inverse probability of treatment weighting and propensity score-matching analyses. Regarding treatment-related adverse events, the HAIC-maintain group showed worse profiles in terms of leukopenia (all grades [p = 0.001] and grades 3 or 4 [p = 0.041]) and hypoalbuminemia (p = 0.001) than the Sorafenib-maintain group. Conclusions: The overall clinical efficacies between the sequential treatment of HAIC vs. sorafenib after LD-CCRT were comparable for locally advanced HCC. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English, German | - |
dc.publisher | Springer-Verlag | - |
dc.relation.isPartOf | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Sojung Han | - |
dc.contributor.googleauthor | Hye Jin Choi | - |
dc.contributor.googleauthor | Seung-Hoon Beom | - |
dc.contributor.googleauthor | Hye Rim Kim | - |
dc.contributor.googleauthor | Hyein Lee | - |
dc.contributor.googleauthor | Jae Seung Lee | - |
dc.contributor.googleauthor | Hye Won Lee | - |
dc.contributor.googleauthor | Jun Yong Park | - |
dc.contributor.googleauthor | Seung Up Kim | - |
dc.contributor.googleauthor | Do Young Kim | - |
dc.contributor.googleauthor | Sang Hoon Ahn | - |
dc.contributor.googleauthor | Kwang-Hyub Han | - |
dc.contributor.googleauthor | Jinsil Seong | - |
dc.contributor.googleauthor | Jong Yun Won | - |
dc.contributor.googleauthor | Beom Kyung Kim | - |
dc.identifier.doi | 10.1007/s00432-021-03632-4 | - |
dc.contributor.localId | A00385 | - |
dc.contributor.localId | A00487 | - |
dc.contributor.localId | A00654 | - |
dc.contributor.localId | A01675 | - |
dc.contributor.localId | A04581 | - |
dc.contributor.localId | A01956 | - |
dc.contributor.localId | A02226 | - |
dc.contributor.localId | A02443 | - |
dc.contributor.localId | A05963 | - |
dc.contributor.localId | A03318 | - |
dc.contributor.localId | A04219 | - |
dc.contributor.localId | A04268 | - |
dc.relation.journalcode | J01283 | - |
dc.identifier.eissn | 1432-1335 | - |
dc.identifier.pmid | 33893539 | - |
dc.identifier.url | https://link.springer.com/article/10.1007%2Fs00432-021-03632-4 | - |
dc.subject.keyword | Concurrent chemoradiotherapy | - |
dc.subject.keyword | Hepatic arterial infusion chemotherapy | - |
dc.subject.keyword | Hepatocellular carcinoma | - |
dc.subject.keyword | Maintenance | - |
dc.subject.keyword | Sorafenib | - |
dc.contributor.alternativeName | Kim, Do Young | - |
dc.contributor.affiliatedAuthor | 김도영 | - |
dc.contributor.affiliatedAuthor | 김범경 | - |
dc.contributor.affiliatedAuthor | 김승업 | - |
dc.contributor.affiliatedAuthor | 박준용 | - |
dc.contributor.affiliatedAuthor | 범승훈 | - |
dc.contributor.affiliatedAuthor | 성진실 | - |
dc.contributor.affiliatedAuthor | 안상훈 | - |
dc.contributor.affiliatedAuthor | 원종윤 | - |
dc.contributor.affiliatedAuthor | 이재승 | - |
dc.contributor.affiliatedAuthor | 이혜원 | - |
dc.contributor.affiliatedAuthor | 최혜진 | - |
dc.contributor.affiliatedAuthor | 한광협 | - |
dc.citation.volume | 147 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 3123 | - |
dc.citation.endPage | 3133 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, Vol.147(10) : 3123-3133, 2021-10 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.